Onco Wiki / Indication

Pheochromocytoma and paraganglioma (PPGL) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Trackaggressive
Linked regimenNone
IDIND-SDHB-CARRIER-INTENSIFIED
TypeIndication
Statusreviewed 2026-05-20 | pending_clinical_signoff
DiseasesDIS-PHEOCHROMOCYTOMA
SourcesSRC-ENDOCRINE-SOCIETY-MEN-2023 SRC-NCCN-NET-2025

Notes

STUB — v0.3 gene-specific PGL4 (SDHB) further-intensified surveillance track. Sibling — IND-SDHB-CARRIER-SURVEILLANCE (standard intensive track). CRITICAL severity inherited from RF. §15.2 C4 ≥2-tracks invariant.

Used By

Indication

Red flag